- Patients meeting eligibility criteria will receive CRLX101 (IV Q 2weeks) plus olaparib (PO BID days 3-13 and days 17-26 administered in 28 day cycles, until disease progression or development of intolerable side effects. The MTD of the combination will be used in Phase II.